Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GNPAT | O15228 | 2/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9800504 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL648867 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL159460 | 0.88 | GNPAT (0.55) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL159461 | 0.88 | GNPAT (0.55) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL159459 | 0.88 | GNPAT (0.55) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL919220 | 0.86 | FOLH1 (0.62) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL31002555 | 0.86 | GNPAT (0.54) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL20530 | 0.86 | FOLH1 (0.62) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL29390797 | 0.86 | GNPAT (0.54) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL20529 | 0.86 | FOLH1 (0.62) | SMN1; SMN2KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114134127-A | Diaminobutyrate acetyltransferase mutants for the synthesis of ectoin | 上海邦林生物科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | claimed |
| US-9290551-B2 | Compounds for treating papilloma virus infection | NANOVIR LLC (US) | 2016-03-22 | — | — | US | claimed |
| WO-2016022664-A1 | ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING INFECTIONS CAUSED BY DOUBLE-STRANDED DNA VIRUSES | NANOVIR LLC (US) | 2016-02-11 | — | — | WO | claimed |
| US-20150329596-A1 | ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING INFECTIONS CAUSED BY DOUBLE-STRANDED DNA VIRUSES | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-11-19 | — | — | US | claimed |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-08-27 | — | — | US | claimed |
| US-8993609-B2 | Compounds for treating papilloma virus infection | NANOVIR, LLC (US) | 2015-03-31 | — | — | US | claimed |
| WO-2014065848-A2 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | BASHKIN JAMES K (US) | 2014-05-01 | — | — | WO | claimed |
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | NANOVIR, LLC (US) | 2012-09-06 | — | — | US | claimed |
| US-8119677-B2 | Polyamides containing amino butyric acid-based building blocks | NANOVIR, LLC (US) | 2012-02-21 | — | — | US | claimed |
| CN-101698662-A | Artificial synthesis method of 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carboxylic acid | UNIV SHANDONG | 2010-04-28 | — | — | CN | claimed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | claimed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | claimed |
| CN-116987649-B | Genetically engineered bacterium for efficiently producing ectoin and preparation and application thereof | 山东泓达生物科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12209252-B2 | Transduction buffer | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2025-01-28 | — | — | US | disclosed |
| EP-3954390-B1 | TRANSDUCTION BUFFER | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2024-08-07 | — | — | EP | disclosed |
| CN-101698662-A | Artificial synthesis method of 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carboxylic acid | UNIV SHANDONG | 2010-04-28 | — | — | CN | disclosed |
| CN-101698662-A | Artificial synthesis method of 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carboxylic acid | UNIV SHANDONG | 2010-04-28 | — | — | CN | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | SMN1; SMN2 4595/4885KDM4E 2048/4885MAPT 2213/4885 |
| US-20150329596-A1 | ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING INFECTIONS CAUSED BY DOUBLE-STRANDED DNA VIRUSES | POLI, POLL, PCNA | SMN1; SMN2 2849/4885KDM4E 2238/4885MAPT 2713/4885 |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | POLI, VHL, TLR3 | SMN1; SMN2 4478/4885KDM4E 2155/4885MAPT 3325/4885 |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | SMN1; SMN2 4595/4885KDM4E 2048/4885MAPT 2213/4885 |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | POLI, PMAIP1, TLR3 | SMN1; SMN2 4689/4885KDM4E 1638/4885MAPT 2258/4885 |
| US-12209252-B2 | Transduction buffer | STAT3, JAK2, CFTR | SMN1; SMN2 3021/4885KDM4E 4597/4885MAPT 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.